HIV PreventionPhase 1STARSNCT01028157
S.T.A.R.S.: Sistas Talking About Real Solutions
A Phase 1 study testing STARS: Sistas Talking About Real Solutions and General Health & Nutrition in people with HIV Prevention, run by Emory University at 1 site in United States.
Trial summary
STARS: Sistas Talking About Real Solutions is a health education intervention for African-American women, ages 18-29 aimed at reducing their risk for HIV. A total of 855 subjects were recruited from three Kaiser Permanente Medical Centers. Read more about this study
- Who is it for?
- Ages 18 to 29 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- HIV Prevention
- What is being tested?
- STARS: Sistas Talking About Real Solutions and General Health & Nutrition
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 855 participants
- Where
- 1 siteUnited States
- Study dates
- Oct 2002to Mar 2006
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 29 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- African American
- female
- Age 18-29
- unmarried
- engaged in at least one act of unprotected sexual intercourse within the last 6 months
- were members of one of the three Kaiser Permanente HMO study sites
Who cannot join
- pregnant or trying to get pregnant
- young adults who have a condition that precludes participation (i.e. schizophrenia, severe learning disability, or undergoing chemotherapy)
Trial locations and contacts
1 site in 1 country.
United States1 site
Emory University, Rollins School of Public Health
Atlanta, Georgia, 30322
About this study
Official title: STARS: Sistas Talking About Real Solutions
STARS: Sistas Talking About Real Solutions is a health education intervention for African-American women, ages 18-29 aimed at reducing their risk for HIV. A total of 855 subjects were recruited from three Kaiser Permanente Medical Centers. Members were randomly selected from the membership database and sent a letter via mail introducing them to the project and inviting them to participate. Letters were followed up with a phone call and potential participants were screened for eligibility. To be able to participate, participants had to be African-American, female, between the ages of 18-29, single, and have at least one act of unprotected sexual intercourse within the last 6 months. Members who were eligible and willing to participate completed a 1-hour baseline assessment survey; STD testing for Chlamydia, gonorrhea, trichomoniasis, and HPV; a vaginal swab that was used to determine if they had unprotected sex. They were then randomized into one of two study conditions: (1) a 2-session HIV risk-reduction condition with a safer sex relapse prevention component (2) a 1-session control condition in which participants receive general women's health information and brochures. Participants received a booster session at 6 and 9 months to reinforce intervention materials. Participants completed an assessment survey and received STD testing at 6 and 12 months. The primary aim of this project is to evaluate the efficacy of the HIV risk-reduction/safer sex relapse prevention condition relative to the health and nutritional control group in reducing HIV-associated sexual behaviors and incident STDs over a 12-month follow-up period is to implement.
Read the detailed description
The primary aims of the study are: 1) to evaluate the efficacy of the HIV risk-reduction, safer sex relapse prevention condition relative to the general health and nutrition control condition in reducing HIV-associated sexual behaviors and incident STDs over a 12-month follow-up period; 2) to evaluate the efficacy of the HIV risk-reduction, safer sex relapse prevention condition relative to the general health and nutrition control condition in enhancing theoretically-derived mediators of HIV-preventive behaviors.
The study began recruitment into the main trial in October, 2002. By the close of the recruitment window in March 2006, 855 African American women had been randomized to either of the study conditions. The study participants were eligible if they were: (a) unmarried, (b) African American women, (c) ages 18-29, (d) not pregnant, (e) reported at least one act of unprotected sexual intercourse within the last 6 months and, (f) were members of one of the three Kaiser Permanente HMO study sites. The three medical facilities included the Cascade Kaiser Permanente Center, the Southwood Kaiser Permanente Center and, the Panola Kaiser Permanente Center. While there are other Kaiser Permanente Medical facilities in Atlanta, these sites were selected because of the high prevalence of African-American women.
Once recruited via a random selection process, participants returned to a Kaiser Medical Center on a specified Saturday morning for their baseline visit. At the baseline visit participants were: (1) provided a brief overview of the STARS study; (2) provided written informed consent; (3) asked to complete a one hour ACASI survey; (4) asked to provide self-obtained vaginal swab specimen that were assessed for four STDs (Chlamydia, gonorrhea, trichomonas, and human papilloma virus) and a new PCR procedure to detect the presence of sperm in vaginal specimen and; (5) randomized to one of the two study conditions using concealment of allocation techniques to minimize assignment bias.
The ACASI is guided by the Theory of Gender and Power and Social Cognitive Theory. The interview has sections on sociodemographics, sexual history, alcohol and drug use, attitudes and outcome expectations related to abstinence and condom use, peer norms, and stress and coping. The administration of the ACASI interview was enhanced by the inclusion of a 60-day calendar that participants complete prior to the interview. This allows a more realistic time frame to reference interview questions and time for the participant to recall and document behavior before beginning the interview. Upon completion of the full assessment, participants provided swabs for STI specimens. All participants with a positive test result were offered free directly observed therapy (DOT) at their participating medical center.
Participants were randomized to one of two study conditions: (1) an HIV safer sex risk-reduction condition with a relapse prevention component and; (2) a general health and nutrition control condition. the HIV safer sex risk-reduction condition consisted of two 4-hour safer sex workshops; the two workshops were guided by the Theory of Gender and Power and Social Cognitive Theory and; held on consecutive Saturdays at the participating medical centers. The sessions were implemented by a team of African American female health educators and had on average of 6 - 8 participants per session. The two study conditions are outlined below:
The HIV safer sex risk-reduction condition with a relapse prevention component: Participants in this condition received the two 4-hour safer sex workshops. The first workshop focused on enhancing ethnic and gender pride, self-esteem, realizing values and setting goals, healthy vs. unhealthy relationships, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options. The second workshop offered realistic choices in sexual decision making, covering topics including abstinence, masturbation, oral, vaginal, and anal sex. The risk and benefits related to each safer-sex option were examined. Participants also received instruction on safer-sex skills corresponding to each option. Consistent and proper condom use was also discussed and demonstrated with a module on condom skills. This module included activities demonstrating the increased difficulty of proper condom use when under the influence of substances such and drugs and alcohol. Modules on setting limits and boundaries, communication styles, and condom skills negotiation were also a part of this workshop. In addition, an activity was included on indications and ways to deal with partner violence. Workshop II included several role-play scenarios demonstrating how to handle excuses related to safer-sex options and also exhibiting realistic situations that women may face in their sexual relationships. Participants in this condition received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. The 6-month booster session included modules that reinforced concepts such as gender and ethnic pride, self-esteem, communicating safer-sex options, assertive communication skills, difficulties communicating with long-term partners, and standing by one's safer-sex decisions. Again, role plays and interactive activities facilitated participants' ability to explore and examine challenges they experienced related to these topics. In a similar fashion, the 9-month booster session reinforced positive safer-sex messages, exploration of past unsafe sexual experiences, mastering safer sex techniques, identifying and making wise decisions about healthy and unhealthy partner characteristics, creative options for safer sex, gender and ethnic pride, and empowerment to make and maintain healthy choices. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
The control condition: Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
Participants in all study conditions received a group introduction including group guidelines, definition of a 'STARS Sista', the STARS motto, pact and group contract.
Follow-up visits: At the 6-month follow-up visit all participants completed the 6-month ACASI to assess potential behavior change and change in the study mediators; and provided specimens for Chlamydia, gonorrhea and trichomoniasis; and provided a specimen for the PCR procedure to detect the presence of sperm in a vaginal sample.
At the 12-month follow-up visit participants completed the 12-month ACASI to assess potential behavior change and change in the study mediators; provided specimens for Chlamydia, gonorrhea and trichomoniasis and HPV (if they did not test positive for HPV at baseline); and provided a specimen for the PCR procedure to detect the presence of sperm in a vaginal sample.
- Conditions
- HIV Prevention
- Being tested
- STARS: Sistas Talking About Real Solutions, General Health & Nutrition
- Keywords
- HIV, risk reduction, behavioral intervention
- Medical subject headings
- Risk Reduction Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
STARS: Sistas Talking About Real SolutionsBehavioural
Also called Risk reduction, safer sex options
The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
General Health & NutritionBehavioural
Also called Placebo, Control, Health Control
Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
| Study group | Role | What they receive |
|---|---|---|
| General Health Control | Placebo comparator | Not described Receives: Behavioral: General Health & Nutrition |
| HIV Risk Reduction & Relapse Prevention | Experimental | Not described Receives: Behavioral: STARS: Sistas Talking About Real Solutions |
What is being measured
The primary outcome is the main question the study is designed to answer.
To evaluate the efficacy of a HIV risk-reduction condition relative to general health control condition in reducing HIV-associated sexual behaviors and incident STDs.
Measured: 12 months
Secondary outcomes (1)
To evaluate the efficacy of a HIV risk-reduction condition relative to general health control condition in enhancing theoretically-derived mediators of HIV-preventive behaviors.
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2009 (estimated)
- Study startOct 2002
- Primary completionMar 2006
- Study completionMar 2006
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HIV PreventionStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 855 participants (actual)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Responsible party
- Principal investigator, Gina M Wingood, Emory University
- Investigators
- Gina M Wingood, ScD, MPH, Principal investigator, Emory UniversityLaShun R Robinson, PhD, Study director, Emory UniversityRalph DiClemente, PhD, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01028157
- Sponsor's protocol ID
- 0524-2002
- Other IDs
- 5R01MH062717
- Acronym
- STARS
- Status last verified
- Dec 2013
- First submitted
- 4 Dec 2009
- Last updated
- 17 Dec 2013
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Dec 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- STARS: Sistas Talking About Real Solutions
- ClinicalTrials.gov ID
- NCT01028157
- Acronym / sponsor ID
- STARS / 0524-2002
- Conditions
- HIV Prevention
- Keywords
- HIV, risk reduction, behavioral intervention
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 855 participants (actual)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Collaborators
- National Institute of Mental Health (NIMH)
- Study start
- Oct 2002
- Primary completion
- Mar 2006 (actual)
- Study completion
- Mar 2006 (actual)
- First posted
- 9 Dec 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
STARS: Sistas Talking About Real Solutions is a health education intervention for African-American women, ages 18-29 aimed at reducing their risk for HIV. A total of 855 subjects were recruited from three Kaiser Permanente Medical Centers. Members were randomly selected from the membership database and sent a letter via mail introducing them to the project and inviting them to participate. Letters were followed up with a phone call and potential participants were screened for eligibility. To be able to participate, participants had to be African-American, female, between the ages of 18-29, single, and have at least one act of unprotected sexual intercourse within the last 6 months. Members who were eligible and willing to participate completed a 1-hour baseline assessment survey; STD testing for Chlamydia, gonorrhea, trichomoniasis, and HPV; a vaginal swab that was used to determine if they had unprotected sex. They were then randomized into one of two study conditions: (1) a 2-session HIV risk-reduction condition with a safer sex relapse prevention component (2) a 1-session control condition in which participants receive general women's health information and brochures. Participants received a booster session at 6 and 9 months to reinforce intervention materials. Participants completed an assessment survey and received STD testing at 6 and 12 months. The primary aim of this project is to evaluate the efficacy of the HIV risk-reduction/safer sex relapse prevention condition relative to the health and nutritional control group in reducing HIV-associated sexual behaviors and incident STDs over a 12-month follow-up period is to implement.
Detailed description
The primary aims of the study are: 1) to evaluate the efficacy of the HIV risk-reduction, safer sex relapse prevention condition relative to the general health and nutrition control condition in reducing HIV-associated sexual behaviors and incident STDs over a 12-month follow-up period; 2) to evaluate the efficacy of the HIV risk-reduction, safer sex relapse prevention condition relative to the general health and nutrition control condition in enhancing theoretically-derived mediators of HIV-preventive behaviors.
The study began recruitment into the main trial in October, 2002. By the close of the recruitment window in March 2006, 855 African American women had been randomized to either of the study conditions. The study participants were eligible if they were: (a) unmarried, (b) African American women, (c) ages 18-29, (d) not pregnant, (e) reported at least one act of unprotected sexual intercourse within the last 6 months and, (f) were members of one of the three Kaiser Permanente HMO study sites. The three medical facilities included the Cascade Kaiser Permanente Center, the Southwood Kaiser Permanente Center and, the Panola Kaiser Permanente Center. While there are other Kaiser Permanente Medical facilities in Atlanta, these sites were selected because of the high prevalence of African-American women.
Once recruited via a random selection process, participants returned to a Kaiser Medical Center on a specified Saturday morning for their baseline visit. At the baseline visit participants were: (1) provided a brief overview of the STARS study; (2) provided written informed consent; (3) asked to complete a one hour ACASI survey; (4) asked to provide self-obtained vaginal swab specimen that were assessed for four STDs (Chlamydia, gonorrhea, trichomonas, and human papilloma virus) and a new PCR procedure to detect the presence of sperm in vaginal specimen and; (5) randomized to one of the two study conditions using concealment of allocation techniques to minimize assignment bias.
The ACASI is guided by the Theory of Gender and Power and Social Cognitive Theory. The interview has sections on sociodemographics, sexual history, alcohol and drug use, attitudes and outcome expectations related to abstinence and condom use, peer norms, and stress and coping. The administration of the ACASI interview was enhanced by the inclusion of a 60-day calendar that participants complete prior to the interview. This allows a more realistic time frame to reference interview questions and time for the participant to recall and document behavior before beginning the interview. Upon completion of the full assessment, participants provided swabs for STI specimens. All participants with a positive test result were offered free directly observed therapy (DOT) at their participating medical center.
Participants were randomized to one of two study conditions: (1) an HIV safer sex risk-reduction condition with a relapse prevention component and; (2) a general health and nutrition control condition. the HIV safer sex risk-reduction condition consisted of two 4-hour safer sex workshops; the two workshops were guided by the Theory of Gender and Power and Social Cognitive Theory and; held on consecutive Saturdays at the participating medical centers. The sessions were implemented by a team of African American female health educators and had on average of 6 - 8 participants per session. The two study conditions are outlined below:
The HIV safer sex risk-reduction condition with a relapse prevention component: Participants in this condition received the two 4-hour safer sex workshops. The first workshop focused on enhancing ethnic and gender pride, self-esteem, realizing values and setting goals, healthy vs. unhealthy relationships, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options. The second workshop offered realistic choices in sexual decision making, covering topics including abstinence, masturbation, oral, vaginal, and anal sex. The risk and benefits related to each safer-sex option were examined. Participants also received instruction on safer-sex skills corresponding to each option. Consistent and proper condom use was also discussed and demonstrated with a module on condom skills. This module included activities demonstrating the increased difficulty of proper condom use when under the influence of substances such and drugs and alcohol. Modules on setting limits and boundaries, communication styles, and condom skills negotiation were also a part of this workshop. In addition, an activity was included on indications and ways to deal with partner violence. Workshop II included several role-play scenarios demonstrating how to handle excuses related to safer-sex options and also exhibiting realistic situations that women may face in their sexual relationships. Participants in this condition received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. The 6-month booster session included modules that reinforced concepts such as gender and ethnic pride, self-esteem, communicating safer-sex options, assertive communication skills, difficulties communicating with long-term partners, and standing by one's safer-sex decisions. Again, role plays and interactive activities facilitated participants' ability to explore and examine challenges they experienced related to these topics. In a similar fashion, the 9-month booster session reinforced positive safer-sex messages, exploration of past unsafe sexual experiences, mastering safer sex techniques, identifying and making wise decisions about healthy and unhealthy partner characteristics, creative options for safer sex, gender and ethnic pride, and empowerment to make and maintain healthy choices. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
The control condition: Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
Participants in all study conditions received a group introduction including group guidelines, definition of a 'STARS Sista', the STARS motto, pact and group contract.
Follow-up visits: At the 6-month follow-up visit all participants completed the 6-month ACASI to assess potential behavior change and change in the study mediators; and provided specimens for Chlamydia, gonorrhea and trichomoniasis; and provided a specimen for the PCR procedure to detect the presence of sperm in a vaginal sample.
At the 12-month follow-up visit participants completed the 12-month ACASI to assess potential behavior change and change in the study mediators; provided specimens for Chlamydia, gonorrhea and trichomoniasis and HPV (if they did not test positive for HPV at baseline); and provided a specimen for the PCR procedure to detect the presence of sperm in a vaginal sample.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| General Health Control | Placebo comparator | Behavioral: General Health & Nutrition |
| HIV Risk Reduction & Relapse Prevention | Experimental | Behavioral: STARS: Sistas Talking About Real Solutions |
Who may qualify
- Ages
- 18 to 29 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- African American
- female
- Age 18-29
- unmarried
- engaged in at least one act of unprotected sexual intercourse within the last 6 months
Key exclusion criteria (2 listed)
- pregnant or trying to get pregnant
- young adults who have a condition that precludes participation (i.e. schizophrenia, severe learning disability, or undergoing chemotherapy)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| STARS: Sistas Talking About Real SolutionsAlso: Risk reduction, safer sex optionsThe intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention. | Behavioural | HIV Risk Reduction & Relapse Prevention |
| General Health & NutritionAlso: Placebo, Control, Health ControlParticipants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided. | Behavioural | General Health Control |
Primary outcome
To evaluate the efficacy of a HIV risk-reduction condition relative to general health control condition in reducing HIV-associated sexual behaviors and incident STDs.
Time frame: 12 months
1 secondary outcome
To evaluate the efficacy of a HIV risk-reduction condition relative to general health control condition in enhancing theoretically-derived mediators of HIV-preventive behaviors.
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Dec 2013.
Related trials for HIV Prevention
Not yet recruiting
HealthMpowerment Korea: Pilot Testing the Cultural Adaptation of a Digital HIV Intervention for Men Who Have Sex With Men in South Korea
HIV Infections, HIV Prevention and Care
Not yet recruiting
HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking
HIV Testing, STI
Not yet recruiting
HC-HMP: Healthy Choices Implementation Trial
Alcohol Drinking, HIV Infections
Not yet recruitingPhase 4
NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings
HIV Infections, Opioid Use Disorder
Active, not recruitingPhase 3
Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)
HIV Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gina M Wingood, ScD, MPH principal investigator
Emory University
LaShun R Robinson, PhD study director
Emory University
Ralph DiClemente, PhD principal investigator
Emory University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing STARS: Sistas Talking About Real Solutions and General Health & Nutrition in people with HIV Prevention, run by Emory University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Dec 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To evaluate the efficacy of a HIV risk-reduction condition relative to general health control condition in reducing HIV-associated sexual behaviors and incident STDs. (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2013.